1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
REGULATORY
Some CSIMC Members Question NHI Pricing of Nexium Priced at Lower Level Than Omepral
The safety of combination drugs containing Takeda Pharmaceutical’s type 2 diabetes treatment Actos (pioglitazone), which has been linked to an increased risk of bladder cancer, was repeatedly questioned at a general assembly of the Central Social Insurance Medical Council (CSIMC;…
To read the full story
REGULATORY
- MHLW to Shorten Procedure for Generic Product Integration to 1.5 Months
February 21, 2025
- Takeda’s Livmarli, BMS’s Camzyos and More Up for MHLW Panel Review on March 6
February 21, 2025
- Japan to Pen Fact Sheet for Sanofi’s High-Dose Flu Jab
February 21, 2025
- Japan Approves CSL’s HAE Med Andembry, Tecentriq Sarcoma Use, and More
February 21, 2025
- Ex-Lawmakers Launch Council for Revamping Japan’s Drug Innovation
February 20, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…